MX2020010075A - Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. - Google Patents
Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.Info
- Publication number
- MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A
- Authority
- MX
- Mexico
- Prior art keywords
- lysin
- constructs
- lysines
- encode
- isolated
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 239000004472 Lysine Substances 0.000 title 1
- 150000002669 lysines Chemical class 0.000 title 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650235P | 2018-03-29 | 2018-03-29 | |
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US201862722793P | 2018-08-24 | 2018-08-24 | |
| PCT/US2019/024912 WO2019191633A2 (en) | 2018-03-29 | 2019-03-29 | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010075A true MX2020010075A (es) | 2021-01-08 |
Family
ID=68060804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010075A MX2020010075A (es) | 2018-03-29 | 2019-03-29 | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773140B2 (enExample) |
| EP (1) | EP3775192A4 (enExample) |
| JP (1) | JP2021519083A (enExample) |
| KR (1) | KR20200136980A (enExample) |
| CN (1) | CN112368376A (enExample) |
| AU (1) | AU2019245369A1 (enExample) |
| BR (1) | BR112020019484A2 (enExample) |
| CA (1) | CA3095484A1 (enExample) |
| IL (1) | IL277119B2 (enExample) |
| MX (1) | MX2020010075A (enExample) |
| WO (1) | WO2019191633A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015279705B2 (en) * | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| US20210330738A1 (en) * | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2020046747A1 (en) * | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3946609A4 (en) * | 2019-04-05 | 2023-05-03 | Contrafect Corporation | LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM |
| WO2021007107A1 (en) * | 2019-07-05 | 2021-01-14 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria |
| US20220411473A1 (en) * | 2019-11-14 | 2022-12-29 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
| WO2022204280A1 (en) * | 2021-03-26 | 2022-09-29 | Contrafect Corporation | Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria |
| WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
| FR3149202B1 (fr) * | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| EP4719330A1 (en) * | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149203B1 (fr) * | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| FR3149209B1 (fr) * | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| WO2024256710A2 (en) | 2023-06-15 | 2024-12-19 | Aurobac Therapeutics Sas | Engineered lysin polypeptide constructs active against gram-negative bacteria |
| WO2025054593A2 (en) * | 2023-09-07 | 2025-03-13 | The Trustees Of The University Of Pennsylvania | Molecular de-extinction of antibiotics enabled by deep learning |
| CN120924524B (zh) * | 2025-10-14 | 2026-01-06 | 中国海洋大学 | 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007005520A (es) | 2004-11-12 | 2007-07-09 | Novozymes As | Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican los mismos. |
| CA2765657A1 (en) | 2009-06-16 | 2010-12-23 | Tokai University | Anti-gram-negative bacteria agent |
| KR101701890B1 (ko) * | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
| DK2445515T3 (en) * | 2009-06-26 | 2016-07-04 | Univ Leuven Kath | antimicrobial agents |
| SG178440A1 (en) | 2009-08-24 | 2012-04-27 | Univ Leuven Kath | New endolysin obpgplys |
| EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| EP2699689A4 (en) | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| US20140120074A1 (en) * | 2011-04-27 | 2014-05-01 | Lysando Ag | Antimicrobial agents |
| WO2012159774A1 (en) | 2011-05-26 | 2012-11-29 | Dsm Ip Assets B.V. | Novel listeria bacteriophage p825n and uses thereof |
| US8790639B2 (en) | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
| KR101391332B1 (ko) * | 2012-05-18 | 2014-05-07 | 연세대학교 산학협력단 | 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지 |
| WO2014001571A1 (en) | 2012-06-29 | 2014-01-03 | Lysando Ag | Composition for use in mycobacteria diagnosis |
| CN102861324A (zh) | 2012-10-17 | 2013-01-09 | 重庆市第三人民医院 | 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂 |
| AU2015279705B2 (en) | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| AU2016324307B2 (en) | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR102000120B1 (ko) | 2017-01-26 | 2019-07-15 | 주식회사 코미팜 | 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물 |
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210330738A1 (en) | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| WO2020046747A1 (en) * | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 CN CN201980036007.XA patent/CN112368376A/zh active Pending
- 2019-03-29 BR BR112020019484-0A patent/BR112020019484A2/pt unknown
- 2019-03-29 US US17/041,691 patent/US11773140B2/en active Active
- 2019-03-29 IL IL277119A patent/IL277119B2/en unknown
- 2019-03-29 EP EP19776817.9A patent/EP3775192A4/en not_active Withdrawn
- 2019-03-29 AU AU2019245369A patent/AU2019245369A1/en not_active Abandoned
- 2019-03-29 KR KR1020207031049A patent/KR20200136980A/ko active Pending
- 2019-03-29 MX MX2020010075A patent/MX2020010075A/es unknown
- 2019-03-29 WO PCT/US2019/024912 patent/WO2019191633A2/en not_active Ceased
- 2019-03-29 CA CA3095484A patent/CA3095484A1/en active Pending
- 2019-03-29 JP JP2020551860A patent/JP2021519083A/ja active Pending
-
2023
- 2023-08-18 US US18/452,038 patent/US20240018192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775192A2 (en) | 2021-02-17 |
| US20240018192A1 (en) | 2024-01-18 |
| WO2019191633A2 (en) | 2019-10-03 |
| CA3095484A1 (en) | 2019-10-03 |
| US20210047374A1 (en) | 2021-02-18 |
| WO2019191633A3 (en) | 2019-11-07 |
| EP3775192A4 (en) | 2022-06-01 |
| AU2019245369A1 (en) | 2020-10-29 |
| IL277119A (en) | 2020-10-29 |
| KR20200136980A (ko) | 2020-12-08 |
| BR112020019484A2 (pt) | 2021-01-12 |
| RU2020129467A (ru) | 2022-05-04 |
| IL277119B2 (en) | 2025-08-01 |
| JP2021519083A (ja) | 2021-08-10 |
| IL277119B1 (en) | 2025-04-01 |
| US11773140B2 (en) | 2023-10-03 |
| CN112368376A (zh) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| MX392683B (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| MX388739B (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
| PE20240817A1 (es) | Mutantes de proteina f de rsv | |
| MX2021013417A (es) | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. | |
| MX2019014504A (es) | Inmunoglobulinas de union a agrecano. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2021001129A (es) | Metodo de purificacion de antigenos. | |
| EA201990822A1 (ru) | Иммуномодулирующие слитые белки | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| BR112016025450A2 (pt) | moduladores de canais de íons e usos dos mesmos | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso |